News | August 17, 2025
AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease
Phase 1 dosing is expected to finish by the end of 2025
Phase 1 dosing is expected to finish by the end of 2025
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
AINU is set to accelerate its expansion footprint, enhance operational capabilities
This will be Aster’s fifth hospital in Bengaluru
The request stemmed from a 2024 lawsuit by Rampart alleging Egg Medical had infringed its patent
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
The new Zigly center features and offers comprehensive veterinary services
Subscribe To Our Newsletter & Stay Updated
